A Conversation with Tom Hudson
AbbVie’s Chief Scientific Officer
Science and innovation are the lifeblood of our company. From drug discovery to clinical trials to regulatory approval, we're pursuing new ways to address patients' most challenging health issues.
Since our launch in 2013, we've invested more than $55 billion in R&D. This enables us to discover and deliver innovative medicines and products that solve serious health issues, enhance people's lives today, and address tomorrow's medical challenges.
We focus on core areas where our proven expertise and bold thinking have the greatest potential to solve unmet needs. These areas are oncology, immunology, neuroscience, eye care, medical aesthetics and other specialty areas.
To develop innovative medicines, you need innovative people. Our teams collaborate across disciplines to connect people and ideas, fueling a culture of curiosity and problem-solving.
Our R&D work fuels a dynamic and diverse pipeline that continues to advance and deliver medicines and solutions for patients.
The need to do more for patients motivates our R&D work. By investing in boundary-pushing approaches, we aim to advance programs with a stronger probability of success and move assets forward faster.